Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says

Sep 06 2016

• By Sue Sutter

Related Content

FDA Panel Considers Dynavax’s <em>Heplisav</em> Safety Database Insufficient

Nov 15 2012

Will Dynavax’ HBV Vaccine Resubmission Make The Safety Grade?

Jan 08 2016

Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults

Dec 19 2008

Dynavax Hep B Vaccine Gets Second Panel Review; Scrutiny On Safety, Superiority

Aug 30 2016

Related Companies

Dynavax Technologies Corporation

GSK plc

Merck & Co., Inc.

Additional Topics

Regulation Advisory Committees Drug Review BioPharmaceutical Liver & Hepatic

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window